As part of the Pharmacovigilance Plan of India, the National Medical Commission (NMC) has ordered all accredited medical colleges and independent PG institutions to enrol as Adverse Drug Reaction Monitoring Centers (AMCs) with the Indian Pharmacopoeia Commission (IPC) as soon as possible (PvPI). The National Medical Commission was established by an act of Parliament known as the NMC Act, 2019 to ensure the availability of sufficient and high-quality medical professionals throughout the nation and to improve access to high-quality and reasonably priced medical education.
IPC has enrolled 652 AMCs nationwide thus far. The Ministry of Health and Family Welfare (MoHFW), Government of India (GoI), approved the PvPI in July 2010 with the main goal of developing a national system for patient safety reporting. PvPI intends for public health programmes (PHPs) to incorporate pharmacovigilance as a crucial element for patient safety.
According to current official sources, India has 654 medical colleges. The number of medical colleges in the nation has increased by 69% since 2014, when there were 387 medical institutions. Also, the number of postgraduate (PG) seats has increased by 107 percent, from 31,185 before to 2014 to 64,559 as of today, and the number of MBBS seats has increased by 94%, from 51,348 to 99,763. The World Health Organization (WHO) Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services, known as the National Coordination Centre (NCC) – PvPI, IPC, Ministry of Health and Family Welfare, Government of India, was established on October 30, 2017.
One of the 25 major industries outlined by the Indian government as part of the ambitious “Make in India” project is the pharmaceutical industry, which is set to receive the boost it needs to realise its full potential. The Indian medicines sector currently ranks ninth in terms of value and third in terms of volume worldwide.